Codexis, Inc.
200 Penobscot Drive
Redwood City, CA 94063
United States
Tel: 650-421-8100
Website: http://www.codexis.com/
About Codexis, Inc.
Codexis is a leading enzyme engineering company leveraging our proprietary CodeEvolver® technology platform to discover and develop novel, high performance enzymes for three healthcare industry pillars: pharmaceutical manufacturing, life sciences, and biotherapeutic discovery & development. The enzymes we produce aim to solve real-world challenges associated with small molecule pharmaceuticals manufacturing, nucleic acid synthesis and genomic sequencing, and - as biotherapeutic candidates - they have the potential to treat challenging diseases. To meet this goal, we look for individuals who are driven, eager to grow and ready to embrace meaningful challenges. We empower employees to be authentic, ambitious, agile and have the courage to take action where they can make a positive impact. Whether you are driven by science, or a different area of expertise, we need you to help us create a brighter future.
Are you ready to join our mission to fight rare diseases? Are you interested in enhancing protein optimization and production? Do you have a passion to help people have better quality of life? Come be part of the Codexis, Inc. team where every day we get to unlock the power of proteins®!
Codexis uses our world-leading CodeEvolver® protein engineering platform to discover novel therapies for the treatment of genetic disorders and other debilitating disease and to develop custom enzymes for a wide range of applications. We engineer proteins with high efficacy and safety with the goal of delivering the therapeutic to patients as an enzyme replacement, mRNA, or gene therapy.
But we can't do it without YOU!
We are rapidly growing, and we are presently seeking to expand our pipeline and diversify applications of our technology platform. We have a number of opportunities for passionate scientists that want to do something
76 articles about Codexis, Inc.
-
Codexis to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
2/10/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that it will report its fourth quarter and fiscal year 2021 financial results on Thursday, February 24, 2022, following the close of market.
-
Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria
1/24/2022
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation (ODD) for CDX-6512 for the treatment of homocystinuria.
-
Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing
12/15/2021
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step quantitative reverse transcription PCR.
-
Codexis to Participate in Upcoming Virtual Healthcare Conferences - Nov 19, 2021
11/19/2021
Codexis, inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in three upcoming virtual investment conferences.
-
Codexis to Present Data Highlighting Two New Therapeutic Discovery Programs at the 14th International Congress of Inborn Errors of Metabolism 2021
11/15/2021
Codexis, inc. announced two oral presentations highlighting its therapeutic discovery programs to develop potential treatments for homocystinuria and maple syrup urine disease at the 14th International Congress of Inborn Errors of Metabolism 2021, taking place from November 21 to November 24, 2021, in Sydney, Australia and virtually.
-
Codexis Appoints Two New Senior Leaders for Human Resources and Corporate Development
11/15/2021
Codexis, Inc. today announced the appointments of Karen Frechou-Armijo as Senior Vice President, Human Resources and Asli Aras, Ph.D., as Vice President, Corporate Development.
-
Codexis to Participate in Upcoming Virtual Healthcare Conferences - Nov 09, 2021
11/9/2021
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in three upcoming virtual investment conferences.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
The SynBio Innovation Accelerator, a Collaboration between Codexis and Casdin Capital, Enables $10 million Investment in Molecular Assemblies, Inc.
11/4/2021
Codexis, Inc. today announced a combined $10 million investment enabled by their SynBio Innovation Accelerator in the Series B funding round of Molecular Assemblies, Inc.
-
Codexis Reports Third Quarter 2021 Financial Results
11/4/2021
Codexis, Inc. today announced financial results for the third quarter ended September 30, 2021 and provided a business update.
-
Codexis and Nestlé Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
11/3/2021
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader in the field of nutritional science, announced today the dosing of the first subject in a Phase 1 study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of CDX-7108.
-
Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin
9/9/2021
Codexis, Inc. announced the amendment and extension of its agreement with Merck, known as MSD outside the United States and Canada, to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin, the active pharmaceutical ingredient in Merck’s JANUVIA® and one of the active ingredients in Merck’s JANUMET®.
-
Codexis to Participate in Upcoming Virtual Healthcare Conferences in September 2021
9/7/2021
Codexis, inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in two upcoming virtual investment conferences.
-
Codexis Confirms Receipt of Follow-on Orders for Proprietary Enzyme Product from Undisclosed Global Pharmaceutical Company
8/25/2021
Codexis, Inc. announced the Company received new purchase orders with an aggregate total value of approximately $15 million for the 2021 supply of a proprietary high performance enzyme used to manufacture a critical intermediate for an Active Pharmaceutical Ingredient in a therapeutic drug for an undisclosed global pharmaceutical company.
-
Codexis Reports Second Quarter 2021 Financial Results
8/5/2021
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced financial results for the second quarter ended June 30, 2021 and provided a business update.
-
Codexis to Report Second Quarter 2021 Financial Results on August 5
7/22/2021
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that it will report its financial results for the second quarter of 2021 on Thursday, August 5, 2021, following the close of market.
-
Codexis Announces Completion of CodeEvolver® License Technology Transfer with Global Pharmaceutical Leader
7/14/2021
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the CodeEvolver® platform technology transfer with Novartis Pharma AG (“Novartis”) today.
-
Codexis Earns Milestone Payment from GlaxoSmithKline
7/7/2021
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver® protein engineering platform technology to GlaxoSmithKline (GSK).
-
Codexis Raises 2021 Guidance Following Receipt of Significant New Order for a Proprietary Enzyme Product
6/17/2021
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, is raising its guidance for 2021, following the receipt of a binding purchase order for up to $13.9 million of a proprietary high performance enzyme product from an undisclosed global pharmaceutical company.
-
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.